Anti-trust lawsuit against Natco Pharma over generic cancer drug dismissed in US

Natco Pharma on December 21  said anti-trust claims against it regarding a generic cancer treatment drug in the US have been dismissed. In September this year, the company had stated that along with Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc and others, it had been named defendants by Louisiana Health Service & Indemnity Company, D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc, regarding anti-cancer treatment medication Pomalidomide.

“The plaintiffs voluntarily dismissed Breckenridge Pharmaceutical Inc and Natco Pharma Ltd from the case. All claims against the company in the litigation have now been dismissed,” Natco Pharma said in a regulatory filing. Breckenridge is the ANDA (Abbreviated New Drug Application) holder and front-end marketing partner for the Pomalidomide capsules generic product in the US, it added.

Natco’s Pomalidomide capsules generic product has not yet launched in the US, the company said.

Related Posts

  • Pharma
  • May 16, 2025
  • 61 views
DCA seizes syrup stocks over misleading fever cure claim

Officials from the Telangana Drugs Control Administration (DCA) have seized stocks of a syrup marketed as a cure for ‘all types of fevers’, citing violation of the Drugs and Magic…

  • Pharma
  • May 15, 2025
  • 119 views
Mankind Pharma Faces Rs 341.86 Cr Tax Demand

New Delhi: Mankind Pharma Ltd on Wednesday said it has received additional tax demands, including interest, of Rs 341.86 crore from the Income Tax authority. The company has received orders…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

DCA seizes syrup stocks over misleading fever cure claim

DCA seizes syrup stocks over misleading fever cure claim

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge